<DOC>
	<DOCNO>NCT01770886</DOCNO>
	<brief_summary>A randomised , double-blind , placebo-controlled , phase I study healthy subject . Safety , pharmacokinetic pharmacodynamic data collect .</brief_summary>
	<brief_title>A Phase I Study Oral UE2343 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject 18 65 year age ( inclusive ) . Female subject postmenopausal surgically sterilize hysterectomy . Female subject negative pregnancy test . Male subject willing use effective method contraception , applicable ( unless anatomically sterile abstain sexual intercourse line prefer usual lifestyle subject ) Day 1 3 month afterwards . Subject Body Mass Index ( BMI ) 1830 kg/m2 . Body Mass Index = Body weight ( kg ) / [ Height ( ) ] 2 . Subject clinically significant abnormal serum biochemistry , haematology urine examination value result suggest infectious systemic disorder . The parameter measure include show Appendix 2 . The Simbec normal range show Appendix 3 . Subject negative urinary drug abuse screen ( Appendix 2 ) ( N.B . positive alcohol result may repeat discretion Investigator ) . Subject negative HIV Hepatitis B C result . Subject clinically significant abnormality 12lead electrocardiogram ( ECG ) . clinically significant abnormality vital sign . willing able comply requirement protocol . satisfy medical examiner fitness participate study . provide write informed consent participate study . Smokers eligible participate study . Relevant abnormality medical history examination , include history dementia , psychiatric , neurological , immunological , respiratory cardiovascular disorder . Particularly exclude subject sign peripheral neuropathy . Abnormal laboratory finding suggest presence systematic disorder . Participation clinical study unlicensed drug previous 4 month , market drug study within previous 3 month . ( N.B . washout period trial define period time elapse last dose previous study first dose next study ) . Known allergy , include allergy chemical like excipients associate UE2343 . Recent clinically significant history drug alcohol abuse . Blood donation great 500 ml previous 3 month . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . Receipt regular prescribe medication within 7 day first study day / receipt vitamin , mineral , herbal remedy nutritional supplement within 7 day first study day . Subjects take long lasting drug 7 day study may exclude physician 's discretion . Inclusion subject take counter drug period review casebycase basis relation safety aspects objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Drug Safety</keyword>
</DOC>